Gilead Sciences, Inc. $GILD Shares Sold by Concord Wealth Partners

Concord Wealth Partners trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 50.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 575 shares of the biopharmaceutical company’s stock after selling 591 shares during the quarter. Concord Wealth Partners’ holdings in Gilead Sciences were worth $64,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of GILD. Smallwood Wealth Investment Management LLC purchased a new position in Gilead Sciences during the 1st quarter valued at about $25,000. Activest Wealth Management boosted its holdings in Gilead Sciences by 2,837.5% during the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares during the period. Goodman Advisory Group LLC purchased a new position in Gilead Sciences during the 1st quarter valued at about $29,000. Colonial Trust Advisors boosted its holdings in Gilead Sciences by 304.3% during the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 213 shares during the period. Finally, Core Alternative Capital boosted its holdings in Gilead Sciences by 370.8% during the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 241 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Stock Performance

Shares of GILD opened at $118.21 on Tuesday. The stock has a 50-day simple moving average of $114.72 and a 200-day simple moving average of $110.30. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The stock has a market capitalization of $146.68 billion, a PE ratio of 23.55, a PEG ratio of 0.80 and a beta of 0.34. Gilead Sciences, Inc. has a 1 year low of $84.34 and a 1 year high of $121.83.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.08 billion during the quarter, compared to analysts’ expectations of $6.95 billion. During the same quarter last year, the business posted $2.01 EPS. The business’s quarterly revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is 62.95%.

Insider Transactions at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the sale, the chief executive officer owned 591,203 shares of the company’s stock, valued at approximately $66,013,726.98. This trade represents a 1.66% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $283,925.00. Following the sale, the chief financial officer directly owned 159,555 shares in the company, valued at $18,120,661.35. This trade represents a 1.54% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 66,000 shares of company stock valued at $7,632,100. Corporate insiders own 0.27% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on GILD. Dbs Bank upgraded Gilead Sciences to a “moderate buy” rating in a report on Friday, September 5th. Daiwa Capital Markets upgraded Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 target price for the company in a report on Tuesday, August 19th. Daiwa America upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 19th. Rothschild & Co Redburn raised their target price on Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a report on Friday, September 12th. Finally, UBS Group lifted their price objective on Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a research note on Friday, August 8th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $118.08.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.